Royalty Pharma plc RPRX
67.30 USD -0.27 (-0.40%)
At closeNov 6, 2026, 5:46 PM EST
68.60 +1.30 +1.93%
After hours · Nov 6, 5:46 PM ET
66.52 Day range 68.15
38.09 52-week range 67.57
- YTD
- +74.17%
- 1 year
- +65.03%
News
benzinga.com Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $78 Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $70 to $78.
seekingalpha.com Royalty Pharma: Unique, Diversified Life Science And Biopharma Pure Play Royalty Pharma plc is the global leader in acquiring biopharmaceutical royalties, offering investors exposure to blockbuster therapies and megatrend-driven growth. RPRX focuses on de-risked,…
marketbeat.com Royalty Pharma Q3 Earnings Call Highlights Royalty Pharma NASDAQ: RPRX reported third-quarter portfolio receipts of $890 million, up 9% from a year earlier, as growth in its diversified royalty portfolio offset declines in certain products.…
seekingalpha.com Royalty Pharma plc (RPRX) Q3 2026 Earnings Call Transcript Royalty Pharma plc (RPRX) Q3 2026 Earnings Call Transcript
zacks.com Compared to Estimates, Royalty Pharma (RPRX) Q3 Earnings: A Look at Key Metrics Although the revenue and EPS for Royalty Pharma (RPRX) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with…
zacks.com Royalty Pharma (RPRX) Q3 Earnings and Revenues Surpass Estimates Royalty Pharma (RPRX) came out with quarterly earnings of $1.21 per share, beating the Zacks Consensus Estimate of $1.18 per share. This compares to earnings of $1.17 per share a year ago.
benzinga.com Royalty Pharma Q3 Adj. EPS $1.21 Beats $1.18 Estimate, Sales $690.000M Miss $796.528M Estimate Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.21 per share which beat the analyst consensus estimate of $1.18 by 2.54 percent. This is a 3.42 percent increase over earnings of $1.17…
globenewswire.com Royalty Pharma reports third quarter 2026 results Portfolio Receipts growth of 9% to $890 million; Royalty Receipts growth of 9% Net cash provided by operating activities of $686 million Raised full year 2026 guidance: Portfolio Receipts expected to…
benzinga.com Here's How Much $100 Invested In Royalty Pharma 10 Years Ago Would Be Worth Today Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 32.09% on an annualized basis producing an average annual return of 45.51%. Currently, Royalty Pharma has a market…
benzinga.com ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test ARM Holdings headlines Wednesday’s reports, with investors looking for evidence that AI-related demand can support the chip designer after a sharp stock pullback. McDonald’s, Novo Nordisk, Uber…
benzinga.com If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 15 years by 6.82% on an annualized basis producing an average annual return of 19.77%. Currently, Royalty Pharma has a market…- benzinga.com Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $67 Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $65 to $67.
benzinga.com If You Invested $100 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 26.07% on an annualized basis producing an average annual return of 39.61%. Currently, Royalty Pharma has a market…- benzinga.com If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 15 years by 4.89% on an annualized basis producing an average annual return of 18.08%. Currently, Royalty Pharma has a market…
benzinga.com Why Is Eli Lilly Stock Falling Tuesday? Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown, and market outlook analyzed.- benzinga.com TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $68 TD Cowen analyst Michael Nedelcovych maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $65 to $68.
benzinga.com Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners Novartis stock falls following Phase 3 clinical trial failures for del-desiran and pelacarsen, impacting Ionis and Royalty Pharma shares.- benzinga.com If You Invested $1000 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 27.34% on an annualized basis producing an average annual return of 40.75%. Currently, Royalty Pharma has a market…
benzinga.com Here’s How Much You Would Have Made Owning Royalty Pharma Stock In The Last 10 Years Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 26.07% on an annualized basis producing an average annual return of 39.56%. Currently, Royalty Pharma has a market…
benzinga.com Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.
benzinga.com JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $62 JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $58 to $62.
benzinga.com Royalty Pharma Q2 Adj. EPS $1.32 Beats $1.28 Estimate, Sales $674.000M Miss $693.190M Estimate Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.28 by 3.13 percent. This is a 15.79 percent increase over earnings of $1.14…
benzinga.com AstraZeneca, GameStop, Snap And Other Big Stocks Moving Lower In Monday’s Pre-Market Session U.S. stock futures higher, AstraZeneca dips on merger talks, Apple down 7.4%, other stocks moving lower in pre-market trading.- benzinga.com Neurimmune Sells Portion Of Its Royalty Interest In Cliramitug To Royalty Pharma For Up To $425M, Including $125M Upfront Neurimmune announced today that it has sold a portion of its royalty interest in cliramitug to Royalty Pharma for up to $425 million, including $125 million upfront. The transaction provides the…
- benzinga.com TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $65 TD Cowen analyst Steve Scala maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $50 to $65.
benzinga.com Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial Teva will advance TEV-'408 into a Phase 2b vitiligo study after Phase 1b data showed skin pigmentation improvements and favorable safety.
benzinga.com Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expanding its portfolio.
benzinga.com Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $66 Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $50 to $66.- benzinga.com JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $58 JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $50 to $58.
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript - benzinga.com Royalty Pharma Q1 Adj. EPS $1.30 Beats $1.21 Estimate, Sales $631.000M Miss $1.235B Estimate Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.30 per share which beat the analyst consensus estimate of $1.21 by 7.44 percent. This is a 22.64 percent increase over earnings of $1.06…
benzinga.com Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $63 Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $61 to $63.
benzinga.com Royalty Pharma Announces R&D Co-Funding Agreement With Johnson & Johnson For Total Of $500M In 2026 And 2027 To Advance Development Of JNJ-4804, Investigational Medicine For Autoimmune Diseases Royalty Pharma plc (NASDAQ:RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance the development…- benzinga.com Zymeworks And Royalty Pharma Enter Into $250M Funding From Royalty-backed Note With Repayments Due From 30% Of Worldwide Tiered Royalties On Ziihera (Zanidatamab-hrii) Owed To Zymeworks From Jazz Pharmaceuticals And BeOne Medicines Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain…
- benzinga.com Zymeworks Secures $250 Million From Royalty Pharma In Royalty-Backed Deal Tied To Ziihera Sales, Pledges 30% Of Future Ziihera Royalties For Repayment Zymeworks Inc. (NASDAQ:ZYME) and Royalty Pharma plc (NASDAQ:RPRX) today announced an agreement for $250 million in funding from Royalty Pharma in the form of a non-recourse royalty-backed note with…
benzinga.com Royalty Pharma Q4 Earnings Report: What Investors Need to Know - benzinga.com Royalty Pharma Q4 Adj. EPS $1.47 Beats $1.33 Estimate, Sales $622.000M Miss $795.915M Estimate Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.47 per share which beat the analyst consensus estimate of $1.33 by 10.86 percent. This is a 26.72 percent increase over earnings of…
- benzinga.com Earnings Scheduled For February 11, 2026
benzinga.com Royalty Pharma's Earnings: A Preview - benzinga.com Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $50 Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $48 to $50.
benzinga.com Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being tested for vitiligo and celiac disease, with new trial results expected in 2026.
benzinga.com Royalty Pharma To Reports Business Update On Jan. 13 At 44th Annual J.P. Morgan Healthcare Conference Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments. Pablo Legorreta, Royalty Pharma's Chief Executive Officer and Chairman of…
benzinga.com Royalty Pharma Raises Quarterly Dividend From $0.22 To $0.235 Per Class A Ordinary Share Royalty Pharma plc (NASDAQ:RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ordinary share, reflecting a 6.8% increase in…
benzinga.com Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight Pharmaceuticals giant, Merck & Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32…
benzinga.com What's Going On With Royalty Pharma Stock Wednesday? Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfront and sales-based milestones.- benzinga.com Royalty Pharma Acquires The Final Portion Of PTC Therapeutics' Remaining Royalty On Roche's Evrysdi For $240M Upfront And Up To $60M In Sales-based Milestones Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired the final portion of PTC Therapeutics' remaining royalty on Roche's Evrysdi for $240 million upfront and up to $60 million in…
benzinga.com Royalty Pharma Acquires Pre-Existing Royalty Interest In Nuvalent's Neladalkib And Zidesamtinib From Undisclosed Third Party For Up To $315M Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an undisclosed third party for up to $315…- benzinga.com TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $45 TD Cowen analyst Steve Scala maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $42 to $45.
benzinga.com Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start FDA placed hold on Denali's drug for Pompe disease, requesting changes to protocol. No additional studies requested. Minimal delays expected.